24 июл. 2024 г. · We evaluated the safety and efficacy of twice-yearly subcutaneous lenacapavir or daily oral F/TAF for HIV prevention in adolescent girls and young women.

26 сент. 2024 г. · The PURPOSE 2 trial reported a 96% reduction in the risk of acquiring HIV among study participants, with 99.9% of individuals using LEN not ...

12 сент. 2024 г. · 99.9% of Participants Did Not Acquire HIV Infection in the Lenacapavir Group, with 2 Incident Cases Among 2,180 Participants –.

26 июл. 2024 г. · The full results of the PURPOSE 1 trial, presented at the 25th International AIDS Conference, demonstrate the safety and efficacy of the long- ...

20 июн. 2024 г. · The company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in ...

Currently under investigation for use as prevention in two large Phase III clinical trials, PURPOSE 1 and PURPOSE 2. Early results from PURPOSE 1 showed no HIV ...

The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting ...

29 авг. 2024 г. · Treatment with subcutaneous lenacapavir in combination with an OBR was well tolerated and resulted in a high rate of virological suppression over 104 weeks.

In the PURPOSE 1 trial, no safety concerns were seen. Side effects associated with lenacapavir were comparable to what has been observed in previous studies.

We sought to explore the efficacy of lenacapavir in various combination regimens as initial and maintenance therapy for HIV.